Literature DB >> 24480152

Glucocorticoid induced leucine zipper inhibits apoptosis of cardiomyocytes by doxorubicin.

David Aguilar1, Joshua Strom1, Qin M Chen2.   

Abstract

Doxorubicin (Dox) is an indispensable chemotherapeutic agent for the treatment of various forms of neoplasia such as lung, breast, ovarian, and bladder cancers. Cardiotoxicity is a major concern for patients receiving Dox therapy. Previous work from our laboratory indicated that glucocorticoids (GCs) alleviate Dox-induced apoptosis in cardiomyocytes. Here we have found glucocorticoid-induced leucine zipper (GILZ) to be a mediator of GC-induced cytoprotection. GILZ was found to be induced in cardiomyocytes by GC treatment. Knocking down of GILZ using siRNA resulted in cancelation of GC-induced cytoprotection against apoptosis by Dox treatment. Overexpressing GILZ by transfection was able to protect cells from apoptosis induced by Dox as measured by caspase activation, Annexin V binding and morphologic changes. Western blot analyses indicate that GILZ overexpression prevented cytochrome c release from mitochondria and cleavage of caspase-3. When bcl-2 family proteins were examined, we found that GILZ overexpression causes induction of the pro-survival protein Bcl-xL. Since siRNA against Bcl-xL reverses GC induced cytoprotection, Bcl-xL induction represents an important event in GILZ-induced cytoprotection. Our data suggest that GILZ functions as a cytoprotective gene in cardiomyocytes.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bcl-xL; Caspase-3; Cell death; Chemotherapy; Nuclear receptor; Steroids

Mesh:

Substances:

Year:  2014        PMID: 24480152      PMCID: PMC4131675          DOI: 10.1016/j.taap.2014.01.013

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  40 in total

1.  Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.

Authors:  J P Krischer; S Epstein; D D Cuthbertson; A M Goorin; M L Epstein; S E Lipshultz
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

2.  A stereological analysis of the effect of adriamycin on the ultrastructure of rat myocardial cells in culture.

Authors:  T P Tobin; B C Abbott
Journal:  J Mol Cell Cardiol       Date:  1980-11       Impact factor: 5.000

Review 3.  Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity.

Authors:  H G Keizer; H M Pinedo; G J Schuurhuis; H Joenje
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

4.  Calpain and mitochondria in ischemia/reperfusion injury.

Authors:  Min Chen; Dong-Jun Won; Stan Krajewski; Roberta A Gottlieb
Journal:  J Biol Chem       Date:  2002-05-31       Impact factor: 5.157

5.  Expression of glucocorticoid-induced leucine zipper (GILZ) in cardiomyocytes.

Authors:  David C Aguilar; Josh Strom; Beibei Xu; Kyle Kappeler; Qin M Chen
Journal:  Cardiovasc Toxicol       Date:  2013-06       Impact factor: 3.231

6.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

7.  Bcl-xL gene transfer protects the heart against ischemia/reperfusion injury.

Authors:  Jianhua Huang; Yoshinori Ito; Masayuki Morikawa; Hiroaki Uchida; Masayoshi Kobune; Katsunori Sasaki; Tomio Abe; Hirofumi Hamada
Journal:  Biochem Biophys Res Commun       Date:  2003-11-07       Impact factor: 3.575

8.  Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.

Authors:  Claus Lindbjerg Andersen; Jens Ledet Jensen; Torben Falck Ørntoft
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

10.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

View more
  6 in total

Review 1.  Glucocorticoid-Induced Leucine Zipper in Central Nervous System Health and Disease.

Authors:  Mythily Srinivasan; Debomoy K Lahiri
Journal:  Mol Neurobiol       Date:  2016-11-26       Impact factor: 5.590

2.  Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.

Authors:  Jan Kroon; Martin Puhr; Jeroen T Buijs; Geertje van der Horst; Daniëlle M Hemmer; Koen A Marijt; Ming S Hwang; Motasim Masood; Stefan Grimm; Gert Storm; Josbert M Metselaar; Onno C Meijer; Zoran Culig; Gabri van der Pluijm
Journal:  Endocr Relat Cancer       Date:  2015-10-19       Impact factor: 5.678

Review 3.  GILZ as a Regulator of Cell Fate and Inflammation.

Authors:  Stefano Bruscoli; Carlo Riccardi; Simona Ronchetti
Journal:  Cells       Date:  2021-12-30       Impact factor: 6.600

4.  A novel biomimetic nanomedicine system with anti-inflammatory and anti-osteoporosis effects improves the therapy efficacy of steroid-resistant nephrotic syndrome.

Authors:  Jian Li; Mingyi Zhao; Xinying Xiang; Qingnan He; Rong Gui
Journal:  J Nanobiotechnology       Date:  2021-12-13       Impact factor: 10.435

Review 5.  Cardiac Cachexia: Unaddressed Aspect in Cancer Patients.

Authors:  Sarama Saha; Praveen Kumar Singh; Partha Roy; Sham S Kakar
Journal:  Cells       Date:  2022-03-14       Impact factor: 6.600

6.  Efficacy of combination triple therapy with vasopressin, steroid, and epinephrine in cardiac arrest: a systematic review and meta-analysis of randomized-controlled trials.

Authors:  Fatemeh Saghafi; Negar Bagheri; Amin Salehi-Abargouei; Adeleh Sahebnasagh
Journal:  J Intensive Care       Date:  2022-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.